Xcout IntelKALA BIO, Inc.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Subscribe to see KALA BIO, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
KALA BIO, Inc. at a glance
KALA BIO, Inc. is a biotech company headquartered in Arlington, United States. It is publicly listed (KALA) with a market capitalisation of $7M. Xcout tracks 35 named people at KALA BIO, Inc., including Avi Minkowitz (CEO, CFO & Director).
KALA BIO, Inc. leadership
- Avi MinkowitzCEO, CFO & Director
- Mary ReumuthChief Financial Officer
- Francis S. MahChief Medical Advisor
- Justin HanesFounder & Chair of the Scientific Advisory Board
- Josiah CraverSenior Vice President & Corporate Controller
- Vincent KosewskiSenior Vice President of Manufacturing & Supply Chain Management
29 more named people on record for KALA BIO, Inc., with roles, board committees and tenure — see the full roster →
KALA BIO, Inc. competitors
A few of KALA BIO, Inc.'s closest competitors — see the full list of competitors and alternatives →
BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
HelixNano is a biotechnology research company headquartered in Boston, Massachusetts, focused on developing advanced mRNA platform technologies for therapeutics.
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing treatments that preserve the sight of individuals impacted by severe eye diseases.
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Kernal Biologics is an onco-selective mRNA therapeutics company located in Cambridge, Massachusetts, that creates mRNA therapies designed to instruct specific cells on how to make proteins.
Get KALA BIO, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on KALA BIO, Inc. in Xcout Intel
- 35 named people with titles, LinkedIn and board committees
- 11 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access